NJ-SOLIDIA-TECHNOLOGIES
15.10.2020 15:02:08 CEST | Business Wire | Press release
Solidia Technologies® CEO Tom Schuler shared the possibility of turning Solidia Concrete into a carbon sink for the planet during his TED Talk at TED and Future Stewards’ Global Countdown Launch. Tom was invited to "The Countdown," a call to action on climate change, to explain how cement and concrete contribute to the global carbon challenge and the potential impact of new production technologies for Solidia Cement™ and Solidia Concrete™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005299/en/
"To address global warming, innovation in both cement production and carbon utilization are absolutely essential," said Tom. "Our new technology for ready-mix concrete is currently being tested for infrastructure applications. And we have already pushed our research beyond that with a technology that enables concrete to become a carbon sink; that means we consume more carbon dioxide (CO2 ) than we emit during production."
Outlining the issue, he explained how concrete contributes to the global carbon challenge because it is made with cement. "For every ton of cement produced, about a ton of CO2 is released into the atmosphere. As a result, the cement industry is the second largest industrial emitter of CO2 , responsible for about eight percent of global emissions."
By changing the chemistry of cement, Solidia both lowers emissions at the cement plant and consumes CO2 in the production of concrete. "Our cement reacts with CO2 instead of water. During curing, the chemical reaction with our cement breaks apart the CO2 molecules and captures the carbon to make limestone that glues the concrete together.”
For production of precast concrete that is cured in kilns, he explained: “When you combine the emissions reduction during cement production with CO2 consumption during curing, we reduce cement’s carbon footprint by up to 70%.”
Describing the different carbon delivery system developed for ready-mix, he added: "Since we can’t use CO2 gas at a construction site, we had to introduce it into our concrete in solid or liquid form. We are partnering with companies that are turning waste CO2 into a family of chemicals, like oxalic or even citric acid – the same one in orange juice. We use these acids to react with our cement and pack in as much as four times more carbon, resulting in carbon-negative concrete.”
Citing the potential impact, Tom explained: “That means that, in just a few hours, one kilometer of road could permanently consume the same amount of CO2 that nearly 100,000 trees absorb in one year. Thanks to chemistry and waste CO2 , we have the potential to transform concrete – the second most utilized material on the planet – into a carbon sink for the planet.”
About Solidia Technologies®
Based in Piscataway, N.J. (USA), Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to create superior and sustainable building and construction materials. At scale each year, Solidia can eliminate at least 1.5 gigatonnes of CO₂, save three trillion liters of fresh water, reduce energy consumption equal to ~260 million barrels of oil, and eliminate 100 million tonnes of concrete landfill waste, while engaging industry in a rapid, globally scalable response to some of the greatest threats facing people and planet. Solidia’s investors include Kleiner Perkins , Bright Capital , BASF , BP , Lafarge Holcim , Total Energy Ventures , Oil and Gas Climate Initiative (OGCI) Climate Investments , Air Liquide , Bill Joy and other private investors. Honors include: the 2020, 2019 and 2014 Global Cleantech 100 ; a 2020 and 2014 Best Place to Work in NJ ; 2020, 2019 and 2018 BP Advancing Low Carbon accreditation; the 2019 Solar Impulse 1000 Efficient Solutions ; 2017 ERA Grand Challenge (formerly CCEMC) finalist; 2016 Sustainia 100 ; 2015 NJBiz Business of the Year; 2014 CCEMC Grand Challenge finalist; 2013 R&D Top 100 ; 2013 Katerva Award finalist; and MIT’s Climate CoLab shortlist. Follow Solidia on LinkedIn , Instagram , Twitter , and YouTube .
About TED
TED is a nonprofit organization devoted to Ideas Worth Spreading, often in the form of short talks delivered by leading thinkers and doers. Many of these talks are given at TED conferences, intimate TED Salons and thousands of independently organized TEDx events around the world. Videos of these talks are made available, free, on TED.com and other platforms. Audio versions of TED Talks are published to TED Talks Daily , available on all podcast platforms.
Follow TED on Twitter , Facebook , Instagram and on LinkedIn . Connect at Countdown@ted.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
